Drug Profile
Research programme: opioid receptor like-1 antagonists - Brane Discovery
Alternative Names: 819555; 848814; BND-001; BND-1 programme; GSK 819555; GSK 848814; NiK-001; ORL-1 orphan receptor antagonists; ORL-1 programme; SB 612111Latest Information Update: 11 Feb 2009
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Brane Discovery
- Class Small molecules
- Mechanism of Action Adenylate cyclase stimulants; Calcium channel agonists; G protein-coupled receptor antagonists; Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders; Neuropathic pain; Parkinson's disease
Most Recent Events
- 12 Jun 2007 This programme is available for partnership opportunities (http://www.branediscovery.com)
- 04 Jun 2007 Brane Discovery acquires this research programme from NiKem Research
- 04 Jun 2007 Preclinical trials in Parkinson's disease in Italy (PO)